Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT02516813 Completed - Clinical trials for Advanced Solid Tumors

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Start date: September 15, 2015
Phase: Phase 1
Study type: Interventional

MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).

NCT ID: NCT02462707 Withdrawn - Clinical trials for Advanced Solid Tumors

A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors

Start date: July 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the recommended Phase 2 dose for PF-03084014 single-agent administration in Japanese patients with advanced solid tumors. Pharmacokinetics and the overall safety profile of PF-03084014 will also be evaluated.

NCT ID: NCT02460224 Completed - Clinical trials for Advanced Solid Tumors

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Start date: June 17, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation (phase 1) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion (phase 2) which characterized treatment of LAG525 in combination with PDR001 at the MTD or RP2D.

NCT ID: NCT02456883 Completed - Clinical trials for Advanced Solid Tumors

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Start date: March 4, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled gilteritinib, in particular, the routes of excretion and extent of metabolism of gilteritinib following administration of a single dose of 14C-labeled gilteritinib after repeated doses of gilteritinib. This study will also evaluate the safety of repeated oral administration of gilteritinib in subjects with advanced solid tumors as well as identify the metabolic profile of gilteritinib in plasma, urine and feces after a single oral dose of 14C-labeled gilteritinib.

NCT ID: NCT02454972 Completed - Clinical trials for Advanced Solid Tumors

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Start date: August 25, 2015
Phase: Phase 2
Study type: Interventional

Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors

NCT ID: NCT02454062 Completed - Clinical trials for Advanced Solid Tumors

A Trial of TAS-114 in Combination With S-1

Start date: March 2013
Phase: Phase 1
Study type: Interventional

A Phase I, Open-Label, International, Multicenter, Non-Randomized, Dose-Escalating Safety, Tolerance and Pharmacokinetic Study of Oral Administration of TAS-114 in Combination with S-1 in a Twice Daily Schedule for 14 Days in Patients with Advanced Solid Tumors.

NCT ID: NCT02448589 Terminated - Clinical trials for Advanced Solid Tumors

An Investigation of TAS-119 Monotherapy

Start date: September 2014
Phase: Phase 1
Study type: Interventional

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumors.

NCT ID: NCT02442414 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

Start date: April 7, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.

NCT ID: NCT02437916 Terminated - Cancer Clinical Trials

Safety Study of AMG 228 to Treat Solid Tumors

Start date: April 21, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.

NCT ID: NCT02432326 Completed - Cancer Clinical Trials

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Start date: April 2015
Phase: Phase 1
Study type: Interventional

This is an open label, multi-center, phase 1 study of BBI608 and BBI503 administered orally in combination to patients with advanced solid tumors. The primary goal is to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination regimen.